Study: Tralokinumab Demonstrates Durable Response, High Retention in AD Patients

Key Takeaways

• Tralokinumab achieved EASI-75 in 83% of patients at 52 weeks in a real-world cohort.

• Study researchers also reported improved quality-of-life and symptom scores over the 1-year study period.

• Treatment was well tolerated; few adverse events were reported.

The long-term use of tralokinumab in adults with moderate-to-severe atopic dermatitis (AD). Over a 52-week period, the IL-13 inhibitor demonstrated clinically meaningful and sustained improvements across multiple outcome measures, with a favorable safety profile and high treatment persistence.

Researchers for the retrospective multicenter study from the Basque Country included 109 adults (mean age 39.4 years; 63.3% male) with moderate-to-severe AD who initiated tralokinumab treatment. Most participants (78%) were naïve of biologics; a majority fo patients had classic disease patterns with head and neck involvement being the most affected area.

According to the results, by week 16, 66% of patients achieved EASI-75 response, 44% reached EASI-90, and 16% achieved EASI-100 (complete clearance). The researchers reported that these rates rose 83%, 70%, and 34%, respectively, by 1 year (52 weeks). Pruritus NRS scores decreased (from 7.1 to 3.1), and DLQI scores decreased from 17.8 to 9.0 over the same period.

Retention was high for patients on tralokinumab at 1 year (70%). Adverse events were uncommon and mild. No serious systemic adverse events were observed.

“These results are consistent with, and in many cases exceed, those observed in pivotal trials and other real-world evidence studies,” the authors wrote in the study. “Our data support the incorporation of tralokinumab into routine clinical practice as a long-term treatment for moderate-to-severe AD, especially in patients with a high burden of disease and comorbidities”.

Source: Belloso RM, et al. J. Clin. Med. 2025.  doi:10.3390/jcm14165727